ArriVent BioPharma, Inc. Common Stock logo AVBP - ArriVent BioPharma, Inc. Common Stock

Price: -- -- | CONSENSUS: Buy DETAILS
STRONG
BUY 0
BUY 6
HOLD 0
SELL 0
STRONG
SELL 0
| PRICE TARGET: $44.00 DETAILS
HIGH: $45.00
LOW: $43.00
MEDIAN: $44.00
CONSENSUS: $44.00
UPSIDE: 64.61%

Stock News

ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case

ArriVent BioPharma: Stronger Balance Sheet And Pipeline Upside Reinforce Our Bull Case

Management reiterated that the move from early 2026 to mid-2026 was driven by slower event accumulation rather than operational issues, enrollment challenges, or trial redesign. ArriVent ended Q1 with $326.4 million of cash and extended its expected runway from Q3 2027 to Q4 2027, reducing near-term funding risk while supporting late-stage development and commercialization efforts. Shanghai Allist continues to demonstrate strong commercial momentum in China, while ARR-002 adds a new potential growth driver.

May 16, 2026 05:32 AM • seekingalpha.com
ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

ArriVent Announces IND Clearance for Novel Tetravalent MUC16/NaPi2b Targeting ADC ARR-002 with Initial Focus in Ovarian and Endometrial Cancers

NEWTOWN SQUARE, Pa., May 07, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced clearance of an investigational new drug (IND) application by the United States Food and Drug Administration (FDA) for ARR-002, a potential first-in-class MUC16/NaPi2b targeting tetravalent antibody-drug conjugate (ADC) with an initial focus in ovarian and endometrial cancers and broader therapeutic potential across solid tumors.

May 07, 2026 04:00 AM • globenewswire.com
ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of “Moderate Buy” by Analysts

ArriVent BioPharma, Inc. (NASDAQ:AVBP) Given Average Recommendation of “Moderate Buy” by Analysts

Shares of ArriVent BioPharma, Inc. (NASDAQ: AVBP - Get Free Report) have earned an average recommendation of "Moderate Buy" from the twelve ratings firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, one has given a hold recommendation, eight have issued a buy recommendation

Apr 23, 2026 10:12 PM • defenseworld.net
ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib

ArriVent BioPharma: Phase 3 Delay May Signal Stronger Outcomes For Firmonertinib

The readout for Firmonertinib has moved to mid-2026, which may reflect slower event accumulation and potentially longer progression-free survival compared with the current standard of care. If the drug delivers PFS above ~10 months with statistical significance, Firmonertinib could capture meaningful market share thanks to its oral monotherapy profile and potentially better safety relative to Rybrevant. With $312 million cash (runway to Q3 2027), the valuation appears asymmetric relative. We remain buyers.

Mar 24, 2026 03:02 AM • seekingalpha.com
ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

ArriVent to Present Two Preclinical Posters on the EGFR Inhibitor Firmonertinib and on the Novel dual-target MUC16/NaPi2b Tetravalent ADC ARR-002 at the 2026 AACR Annual Meeting

NEWTOWN SQUARE, Pa., March 17, 2026 (GLOBE NEWSWIRE) -- ArriVent BioPharma, Inc. (Company or ArriVent) (Nasdaq: AVBP), a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics, today announced two poster presentations at the 2026 American Association for Cancer Research (AACR) Annual Meeting taking place in San Diego, California April 17-22.

Mar 17, 2026 01:00 PM • globenewswire.com

Price Targets